Global /China /Healthcare /Drug Manufacturers - General /688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

688336

• SSE: 688336 • Delayed

73.19CNY 0%

10.78 USD

As of 26 June 2026, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. has a market cap of $6.66B USD, ranking #3029 globally and #528 in China. It ranks #221 in the Healthcare sector, and #82 in the Drug Manufacturers - General industry.

Global Rank

3029

Country Rank

528

Sector Rank

221

Industry Rank

Key Stats

Market Cap

$6.66BUSD

45.23B CNY

Enterprise Value

$6.44BUSD

43.71B CNY

Revenue (TTM)

$636.01MUSD

4.32B CNY

EBITDA (TTM)

$491.67MUSD

3.34B CNY

Net Income (TTM)

$437.99MUSD

2.97B CNY

EBITDA Margin

77%

Profit Margin

69%

PE Ratio

15.3

Forward PE

70.4

PS Ratio

10.5

PB Ratio

5.3

EV/EBITDA

12.8

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Yanli Liu open_in_new

Employees

1,012

Founded

2002

Website

3s-guojian.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-7.4%	2.7%	21%	19%	23%	151%	283%	358%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688336 三生国健药业(上海)股份有限公司 Class A ISIN: CNE1000062X2 Shares Out.: Shares Outstanding: 896.225M¹ Shares Float: 136.925M² TV: TradingView: SSE: 688336 SA: Stock Analysis: SHA: 688336 YF: Yahoo Finance: 688336.SS GF: Google Finance: SHA: 688336 BA: Barron's: 688336 MS: Morningstar: XSHG: 688336	73.19 CNY	TV: TradingView: SSE: 688336 SA: Stock Analysis: SHA: 688336 YF: Yahoo Finance: 688336.SS GF: Google Finance: SHA: 688336 BA: Barron's: 688336 MS: Morningstar: XSHG: 688336

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company was founded in 2002 and is based in Shanghai, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.73B 364.89B CNY 707%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.53B 336.36B CNY 644%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.5B 223.48B HKD 328%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.79B 147.32B HKD 182%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.48B 111.89B CNY 147%	-	China
Akeso, Inc. SHEK: 9926	$16.0B 125.46B HKD 140%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 11K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 8K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 5K%	97.4	United States
Roche Holding AG SIX: RO	$316.45B 256.25B CHF 5K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$284.53B 215.59B GBP 4K%	27.6	United Kingdom
Merck & Co., Inc. NYSE: MRK	$274.03B 4K%	15.1	United States

chevron_leftBack